Clinical dosimetry study of kidney absorbed radiation doses for [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T

被引：0
|
作者：
Uijen, M. [1 ]
Prive, B. [1 ]
van Herpen, C. [1 ]
Gotthardt, M. [1 ]
Konijnenberg, M. [1 ]
Peters, S. [1 ]
Nagarajah, J. [1 ]
机构：
[1] Radboudumc, Nijmegen, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2021年 / 48卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-0284
引用
收藏
页码：S111 / S112
页数：2
相关论文
共 50 条
  • [41] [177Lu]Lu-PSMA-617 (Pluvicto™): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
    Hennrich, Ute
    Eder, Matthias
    [J]. PHARMACEUTICALS, 2022, 15 (10)
  • [42] Predicting benefit from [177Lu]Lu-PSMA-617 therapy: what do we need to know?
    Sartor, Oliver
    [J]. LANCET ONCOLOGY, 2022, 23 (11): : 1344 - 1345
  • [43] BEST PRACTICES IN THE ADMINISTRATION OF [177LU]LU-PSMA-617 RADIOLIGAND THERAPY FOR PROSTATE CANCER IN US CENTERS
    Spitz, Avery
    Gardner, Linda
    Floyd, Rebecca
    Sutton, Jennifer
    [J]. ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [44] Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials
    Di Iorio, Valentina
    Boschi, Stefano
    Cuni, Cristina
    Monti, Manuela
    Severi, Stefano
    Paganelli, Giovanni
    Masini, Carla
    [J]. MOLECULES, 2022, 27 (13):
  • [45] Compounding of [177Lu]Lu-PSMA-I&T using USP grade solvents in the radiopharmacy: experience in Quebec City
    Lafreniere, Nancy
    Beauregard, Jean-Mathieu
    Selivanova, Svetlana
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [46] [225Ac]Ac-PSMA-617 augmented [177Lu]Lu-PSMA-617 RLT in challenging advanced mCRPC patients
    Rosar, F.
    Krause, J.
    Bartholomae, M.
    Maus, S.
    Stemler, T.
    Hierlmeier, I.
    Linxweiler, J.
    Ezziddin, S.
    Khreish, F.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S315 - S315
  • [47] Incorporation Of 177Lu During Care Of 177Lu-PSMA And 177Lu-DOTATATE Therapy Patients
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Kratzel, U.
    Baumgarten, J.
    Ngoc, C. Nguyen
    Garayev, E.
    Gruenwald, F.
    Sabet, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S842 - S843
  • [48] Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling
    Spitz, Avery
    Floyd, Rebecca
    Sutton, Jennifer
    Gardner, Linda
    [J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2023, 27 (05) : 539 - 547
  • [49] Personalized dosimetry assessment of [177Lu]Lu-PSMA-617 radioligand therapy in the management of metastatic castration-resistant prostate cancer
    Kazemi-Jahromi, Mahmood
    Yazdani, Elmira
    Karamzade-Ziarati, Najme
    Asadi, Mahboobeh
    Sadeghi, Mahdi
    Geramifar, Parham
    [J]. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 2024,
  • [50] [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment
    Peters, Steffie M. B.
    Hofferber, Regina
    Prive, Bastiaan M.
    de Bakker, Maarten
    Gotthardt, Martin
    Janssen, Marcel
    de Lange, Frank
    Muselaers, Constantijn H. J.
    Mehra, Niven
    Witjes, J. Alfred
    Costa, Pedro F.
    Nagarajah, James
    Konijnenberg, Mark W.
    Jentzen, Walter
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (04) : 1101 - 1112
12345